Logo

Dharmacon to Provide More siRNAs to Bayer

Mar 02, 2004

NEW YORK, March 2 (GenomeWeb News) - Dharmacon will supply Bayer Pharmaceuticals with siRNA reagents for 4,000 gene targets by the end of March, the company said today.

 

The agreement expands an existing contract the companies announced in November. Bayer plans to use the custom siRNA reagents for internal target validation research.

 

Last month, Fisher Scientific International said it will acquire Lafayette, Colo.-based Dharmacon for $80 million in cash.

Breaking News
The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.